Operator
Good day, everyone, and welcome to Pfizer's second-quarter 2021 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chris Stevo, senior vice president and chief investment relations officer.
Please go ahead, sir.
Senior Vice President and Chief Investment Relations Officer
Thank you, Sylvia. Good morning. It's my pleasure to be welcoming you to Pfizer's second-quarter earnings call for the first time as the head of investor relations at Pfizer. I'm joined today by Dr.
Albert Bourla, our chairman and CEO; Frank D'Amelio, our CFO; Mikael Dolsten, president of worldwide research and development and medical; Angela Hwang, group president, Pfizer Biopharmaceuticals Group; John Young, our chief business officer; and Doug Lankler, general counsel. We'll begin the call with remarks by Albert, followed by a pipeline update from Mikael, and Frank will then give you his thoughts on the numbers and our updated guidance before we open up the call for Q&A. Finally, Albert will come back for concluding comments. We expect this call to last 90 minutes.